Bright Minds Biosciences Stock Revenue

DRUG Stock  USD 35.67  0.60  1.65%   
Bright Minds Biosciences fundamentals help investors to digest information that contributes to Bright Minds' financial success or failures. It also enables traders to predict the movement of Bright Stock. The fundamental analysis module provides a way to measure Bright Minds' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bright Minds stock.
Last ReportedProjected for Next Year
The current Cost Of Revenue is estimated to decrease to about 43.2 K.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bright Minds Biosciences Company Revenue Analysis

Bright Minds' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Historical and Projected quarterly revenue of Bright

Projected quarterly revenue analysis of Bright Minds Biosciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Bright Minds match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Bright Minds' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Bright Minds Biosciences reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.

Bright Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bright Minds' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bright Minds could also be used in its relative valuation, which is a method of valuing Bright Minds by comparing valuation metrics of similar companies.
Bright Minds is currently under evaluation in revenue category among its peers.

Bright Minds ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bright Minds' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bright Minds' managers, analysts, and investors.
Environmental
Governance
Social

Bright Minds Institutional Holders

Institutional Holdings refers to the ownership stake in Bright Minds that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bright Minds' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bright Minds' value.
Shares
Adage Capital Partners Gp Llc2024-12-31
132.5 K
Walleye Trading Advisors, Llc2024-12-31
103.2 K
Schonfeld Strategic Advisors Llc2024-12-31
69.8 K
Longwood Capital Partners Llc2024-12-31
69.1 K
Springhill Fund Asset Management (hk) Co Ltd2024-12-31
60.6 K
Boothbay Fund Management, Llc2024-12-31
44.6 K
Millennium Management Llc2024-12-31
40.4 K
Atika Capital Management Llc2024-12-31
15 K
Ubs Group Ag2024-12-31
10.2 K
Cormorant Asset Management, Llc2024-12-31
1.1 M
Hhg Plc2024-12-31
508.8 K

Bright Fundamentals

About Bright Minds Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bright Minds Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bright Minds using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bright Minds Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Return On Assets
(0.29)
Return On Equity
(0.52)
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.